CR20220231A - Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria - Google Patents

Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria

Info

Publication number
CR20220231A
CR20220231A CR20220231A CR20220231A CR20220231A CR 20220231 A CR20220231 A CR 20220231A CR 20220231 A CR20220231 A CR 20220231A CR 20220231 A CR20220231 A CR 20220231A CR 20220231 A CR20220231 A CR 20220231A
Authority
CR
Costa Rica
Prior art keywords
compounds
naphthyridin
treatment
autoimmune disease
sup
Prior art date
Application number
CR20220231A
Other languages
English (en)
Inventor
Xiaoqing Wang
Wei Zhu
Hongtao Xu
Zhisen Zhang
Hong Shen
Ge Zou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of CR20220231A publication Critical patent/CR20220231A/es
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula (I), en donde R<sup>1</sup> a R<sup>3</sup>, m y n son como se describen en la presente, y su sal farmacéuticamente aceptable, un enantiómero o diastereómero de aquellos, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
CR20220231A 2019-11-26 2022-11-24 Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria CR20220231A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019120996 2019-11-26
PCT/EP2020/083113 WO2021105072A1 (en) 2019-11-26 2020-11-24 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
CR20220231A true CR20220231A (es) 2022-06-27

Family

ID=73598065

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220231A CR20220231A (es) 2019-11-26 2022-11-24 Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria

Country Status (17)

Country Link
US (1) US20230041743A1 (es)
EP (1) EP4065586A1 (es)
JP (1) JP7676391B2 (es)
KR (1) KR20220106126A (es)
CN (1) CN114728987B (es)
AR (1) AR120540A1 (es)
AU (1) AU2020393367A1 (es)
BR (1) BR112022009856A2 (es)
CA (1) CA3156457A1 (es)
CO (1) CO2022006942A2 (es)
CR (1) CR20220231A (es)
IL (1) IL291640A (es)
MX (1) MX2022005912A (es)
PE (1) PE20221026A1 (es)
PH (1) PH12022551012A1 (es)
TW (1) TW202134238A (es)
WO (1) WO2021105072A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210018818A (ko) 2018-06-05 2021-02-18 에프. 호프만-라 로슈 아게 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
JP6248948B2 (ja) * 2013-02-08 2017-12-20 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
PT3889145T (pt) * 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
CN110475777B (zh) * 2017-03-30 2022-04-15 豪夫迈·罗氏有限公司 用于治疗和预防细菌感染的新吡啶并[2,3-b]吲哚化合物
MX2019012431A (es) * 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3807270B1 (en) * 2018-06-12 2023-09-13 F. Hoffmann-La Roche AG Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease

Also Published As

Publication number Publication date
EP4065586A1 (en) 2022-10-05
WO2021105072A1 (en) 2021-06-03
CO2022006942A2 (es) 2022-06-10
PE20221026A1 (es) 2022-06-16
PH12022551012A1 (en) 2023-03-06
BR112022009856A2 (pt) 2022-08-02
MX2022005912A (es) 2022-06-24
IL291640A (en) 2022-05-01
AR120540A1 (es) 2022-02-23
KR20220106126A (ko) 2022-07-28
CA3156457A1 (en) 2021-06-03
CN114728987A (zh) 2022-07-08
JP7676391B2 (ja) 2025-05-14
US20230041743A1 (en) 2023-02-09
JP2023503165A (ja) 2023-01-26
CN114728987B (zh) 2024-08-02
AU2020393367A1 (en) 2022-04-14
TW202134238A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
CR20250329A (es) Compuestos tricíclicos para el tratamiento del cáncer
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
CR20240312A (es) Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias
MX2021006902A (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12021552513A1 (en) Pyrrole compounds
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX380037B (es) Antagonistas novedosos 5-ht2
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
PH12021552953A1 (en) Tricyclic compounds
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
CR20200619A (es) Compuestos de cianotriazol y usos de los mismos
MX2021011575A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
MX2024006176A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno.
MX2019011558A (es) Nuevos compuestos sustituidos de n&#39;-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).